Guardant360® assay is a liquid biopsy that provides fast, accurate and comprehensive genomic results from a simple blood draw. Test results are available in approximately seven days upon receipt in the US laboratory.

The test is done using circulating tumor DNA (ctDNA), which is produced when tumors shed small pieces or their genetic material into the bloodstream.

Guardant360® assay examines a panel of 74 genes (specifications) to identify any alterations in the tumor DNA.

Since its launch in 2014, Guardant360® assay has been ordered by more than 6,000 oncologists over 100,000 times for patients with advanced cancer to help select treatment.

Use and indication
  • Advanced stage – solid tumor -cancer patient with a solid tumor, whose tissue biopsy is insufficient for genetic testing.
  • Advanced stage cancer patient who wants to identify targeted therapy options while avoiding an invasive repeated tissue biopsy.
To know more about Guardant360® assay please visit the or click on this link